Hengrui Pharmaceutical announced that its subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received the “Drug Clinical Trial Approval Notice” for injectable Ruikang trastuzumab approved and issued by the State Drug Administration and will conduct clinical trials in the near future. This drug is a randomized, open, multicenter phase III clinical study of recontrastuzumab monotherapy compared with docetaxe+carboplatin+trastuzumab+pertuzumab as a new adjuvant treatment for early or locally advanced HER2-positive breast cancer. Recon trastuzumab for injection has been approved for marketing in China. It is suitable for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with HER2 activation mutations and who have received at least one type of systematic treatment in the past.

Hengrui Pharmaceutical announced that its subsidiary Suzhou Shengdia Biomedical Co., Ltd. has received the “Drug Clinical Trial Approval Notice” for injectable Ruikang trastuzumab approved and issued by the State Drug Administration and will conduct clinical trials in the near future. This drug is a randomized, open, multicenter phase III clinical study of recontrastuzumab monotherapy compared with docetaxe+carboplatin+trastuzumab+pertuzumab as a new adjuvant treatment for early or locally advanced HER2-positive breast cancer. Recon trastuzumab for injection has been approved for marketing in China. It is suitable for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with HER2 activation mutations and who have received at least one type of systematic treatment in the past.